Physician profile
Fred P Romeo
NPI 1568403814
$2,288,597.39
in general payments reported to CMS, 2019-2025
14 companies · $515K in 2025
The $515K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271K · 2020: $136K · 2021: $231K · 2022: $284K · 2023: $407K · 2024: $445K · 2025: $515K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $907K · Travel and Lodging: $195K · Consulting Fee: $153K · Honoraria: $83K · Food and Beverage: $29K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $907,250.70 |
| Travel and Lodging | $194,516.71 |
| Consulting Fee | $152,972.00 |
| Honoraria | $83,300.00 |
| Food and Beverage | $28,886.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $539,757.48 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $515,243.20 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $472,617.17 | 2020-2025 | Caplyta |
| Alkermes, INC. | $310,188.99 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Axsome Therapeutics, INC. | $231,495.52 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $127,810.02 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $63,027.26 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $9,978.58 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $7,492.31 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $6,310.38 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $4,585.17 | 2024 | Fanapt |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $58.08 | 2021 | |
| Neurocrine Biosciences, INC. | $16.81 | 2019 | |
| Bausch Health US, LLC | $16.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Romeo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.